Chronic, recurrent Lymphocytic Leukemia Completed Phase 2 Trials for Cyclophosphamide (DB00531)

Also known as: Recurrent Chronic Lymphocytic Leukemia

Indication	Status	Phase
DBCOND0112002 (Chronic, recurrent Lymphocytic Leukemia)	Completed	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT00723099	Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	Treatment	Cyclophosphamide (DB00531) Cyclosporine (DB00091) Fludarabine (DB01073) Mycophenolate mofetil (DB00688)
NCT01008462	Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia	Treatment	Beta-D-Glucose (DB02379) Carmustine (DB00262) Cyclophosphamide (DB00531) Cytarabine (DB00987) Etoposide (DB00773) Fludarabine (DB01073) Mechlorethamine (DB00888) Mycophenolate mofetil (DB00688) Tacrolimus (DB00864)